5
-HT1A Receptor Agonist PET Ligand
Journal of Medicinal Chemistry, 2006, Vol. 49, No. 1 133
Acknowledgment. This work was supported by a research
(20) Cumming, P.; Gillings, N. M.; Jensen, S. B.; Bjarkam, C.; Gjedde,
A. Kinetics of the uptake and distribution of the dopamine D(2,3)
agonist (R)-N-[1-(11)C]n-propylnorapomorphine in brain of healthy
and MPTP-treated Gottingen miniature pigs. Nucl. Med. Biol. 2003,
30, 547-553.
grant from the National Institutes of Health (P50 MH62185).
The authors also thank Dr. Bryan Roth and the NIMH-PDSP
program for receptor-transporter assay results.
(
21) Cumming, P.; Wong, D. F.; Gillings, N.; Hilton, J.; Scheffel, U.;
Gjedde, A. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-
norapomorphine to dopamine receptors in living mouse striatum:
occupancy by endogenous dopamine and guanosine triphosphate-
free G protein. J. Cereb. Blood Flow Metab. 2002, 22, 596-604.
22) Narendran, R.; Hwang, D. R.; Slifstein, M.; Talbot, P. S.; Erritzoe,
D.; Huang, Y.; Cooper, T. B.; Martinez, D.; Kegeles, L. S.; Abi-
Dargham, A.; Laruelle, M. In vivo vulnerability to competition by
endogenous dopamine: comparison of the D2 receptor agonist
radiotracer (-)-N-[11C]propyl-norapomorphine ([11C]NPA) with the
D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 2004,
52, 188-208.
Supporting Information Available: Experimental details. This
material is available free of charge via the Internet at
http://pubs.acs.org.
(
References
(
1) Arango, V.; Underwood, M. D.; Boldrini, M.; Tamir, H.; Kassir, S.
A.; Hsiung, S.-C.; Chen, J. J. X.; Mann, J. J. Serotonin 1A Receptors,
Serotonin Transporter Binding and Serotonin Transporter mRNA
Expression in the Brainstem of Depressed Suicide Victims. Neuro-
psychopharmacology 2001, 25, 892-903.
(23) Hirsch, S. R.; Kissling, W.; Bauml, J.; Power, A.; O’Connor, R. A
28-week comparison of ziprasidone and haloperidol in outpatients
with stable schizophrenia. J. Clin. Psychiatry 2002, 63, 516-523.
(24) Passchier, J.; van Waarde, A. Visualisation of serotonin-1A (5-HT1A)
receptors in the central nervous system. Eur. J. Nucl. Med. 2001,
28, 113-129.
(25) Tauscher, J.; Verhoeff, N. P. L. G.; Christensen, B. K.; Hussey, D.;
Meyer, J. H.; Kecojevic, A.; Javanmard, M.; Kasper, S.; Kapur, S.
Serotonin 5-HT1A receptor binding potential declines with age as
measured by [11C]WAY-100635 and PET. Neuropsychopharma-
cology 2001, 24, 522-530.
(26) Pike, V. W.; Halldin, C.; McCarron, J. A.; Lundkvist, C.; Hirani,
E.; Olsson, H.; Hume, S. P.; Karlsson, P.; Osman, S.; Swahn, C.-G.;
Hall, H.; Wikstrom, H.; Mensonidas, M.; Poole, K. G.; Farde, L.
[Carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and
selective radioligand for central 5-HT1A receptors in vitro and in
vivo. Eur. J. Nucl. Med. 1998, 25, 338-346.
(27) Zimmer, L.; Rbah, L.; Giacomelli, F.; Le Bars, D.; Renaud, B. A
reduced extracellular serotonin level increases the 5-HT1A PET
ligand 18F-MPPF binding in the rat hippocampus. J. Nucl. Med. 2003,
44, 1495-1501.
(2) Arango, V.; Huang, Y. Y.; Underwood, M. D.; Mann, J. J. Genetics
of the serotonergic system in suicidal behavior. J. Psychiatr. Res.
2
003, 37, 375-386.
(
3) Sullivan, G. M.; Oquendo, M. A.; Simpson, N.; Van Heertum, R.
L.; Mann, J. J.; Parsey, R. V. Brain serotonin1A receptor binding in
depression is related to psychic and somatic anxiety. Biol. Psychiatry,
in press.
(
4) Merlet, I.; Ostrowsky, K.; Costes, N.; Ryvlin, P.; Isnard, J.; Faillenot,
I.; Lavenne, F.; Dufournel, D.; Le Bars, D.; Mauguiere, F.,3 5-HT1A
receptor binding and intracerebral activity in temporal lobe epi-
lepsy: an [18F]MPPF-PET study. Brain 2004, 127, 900-913.
5) Tiihonen, J.; Keski-Rahkonen, A.; Lopponen, M.; Muhonen, M.;
Kajander, J.; Allonen, T.; Nagren, K.; Hietala, J.; Rissanen, A.,# Brain
serotonin 1A receptor binding in bulimia nervosa. Biol. Psychiatry
(
2
004, 55, 871-873.
(
(
(
6) Meltzer, H. Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors:
their key role in drugs to treat schizophrenia. Prog. Neuropsycho-
pharmacol. Biol. Psychiatry 2003, 27, 1159-1172.
7) Bara-Jimenez, W.; Bibbiani, F.; Morris, M. J.; Dimitrova, T.; Sherzai,
A.; Mouradian, M. M.; Chase, T. N. Effects of serotonin 5-HT1A
agonist in advanced Parkinson’s disease. MoV. Disord. 2005.
8) Lai, M. K. P.; Tsang, S. W. Y.; Francis, P. T.; Esiri, M. M.; Keene,
J.; Hope, T.; Chen, C. P. L. H. Reduced serotonin 5-HT1A receptor
binding in the temporal cortex correlates with aggressive behavior
in Alzheimer disease. Brain Res. 2003, 974, 82-87.
(28) Gozlan, H.; Ponchant, M.; Daval, G.; Verge, D.; Menard, F.;
Vanhove, A.; Beaucourt, J. P.; Hamon, M. 125I-Bolton-Hunter-8-
methoxy-2-[N-propyl-N-propylamino]tetralin as a new selective
radioligand of 5-HT1A sites in the rat brain. In vitro binding and
autoradiographic studies. J. Pharmacol. Exp. Ther. 1988, 244, 751-
759.
(
9) Frazer, A.; Maayani, S.; Wolfe, B. B. Subtypes of receptors for
serotonin. Annu. ReV. Pharmacol. Toxicol. 1990, 30, 307-348.
(29) Ponchant, M.; Beaucourt, J. P.; Vanhove, A.; Daval, G.; Verge, D.;
Hamon, M.; Gozlan, H. [125I-BH-8-MeO-N-PAT, a new ligand for
the study of 5-HT1A receptors in the central nervous system]. C. R.
Acad. Sci. III. 1988, 306, 147-152.
(30) Zhuang, Z. P.; Kung, M. P.; Kung, H. F. Synthesis of (R,S)-trans-
8-hydroxy-2-[N-n-propyl-N-(3′-iodo-2′-propenyl)amino]tetral in (trans-
8-OH-PIPAT): a new 5-HT1A receptor ligand. J. Med. Chem. 1993,
36, 3161-3165.
(31) Halldin, C.; Wikstrom, H.; Swahn, C. G.; Sedvall, G.; Stjernlof, P.;
Farde, L. Preparation of [propyl-11C]OSU 191, a highly potent and
selective 5-HT1A agonist for PET [abstract]. J. Labelled Compd.
Radiopharm. 1994, 35, S675-S677.
(32) Suehiro, M.; Underwood, M.; Arango, V.; Wang, T. S.; Kassir, S.;
Bakalian, M.; Yatabe, T.; Pratap, M.; Van Heertum, R. L.; Mann, J.
J. In vivo biodistribution of a radiotracer for imaging serotonin-1A
receptor sites with PET: [11C]LY274601. Life Sci. 1998, 63, 1533-
1542.
(
(
(
10) Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological
and functional diversity of 5-HT receptors. Pharmacol., Biochem.
BehaV. 2002, 71, 533-554.
11) Hamon, M.; Lanfumey, L.; el Mestikawy, S.; Boni, C.; Miquel, M.
C.; Bolanos, F.; Schechter, L.; Gozlan, H. The main features of central
5-HT1 receptors. Neuropsychopharmacology 1990, 3, 349-360.
12) Radja, F.; Daval, G.; Hamon, M.; Verge, D. Pharmacological and
physicochemical properties of pre-versus postsynaptic 5-hydroxy-
tryptamine1A receptor binding sites in the rat brain: a quantitative
autoradiographic study. J. Neurochem. 1992, 58, 1338-1346.
13) Meltzer, C. C.; Price, J. C.; Mathis, C. A.; Butters, M. A.; Ziolko, S.
K.; Moses-Kolko, E.; Mazumdar, S.; Mulsant, B. H.; Houck, P. R.;
Lopresti, B. J.; Weissfeld, L. A.; Reynolds, C. F. Serotonin 1A
receptor binding and treatment response in late-life depression.
Neuropsychopharmacology 2004, 29, 2258-2265.
(
(
14) Clawges, H. M.; Depree, K. M.; Parker, E. M.; Graber, S. G. Human
5
-HT1 receptor subtypes exhibit distinct G protein coupling behaviors
(33) Mathis, C. A.; Huang, Y.; Simpson, N. R. Synthesis and evaluation
of 5HT1A agonists as radioligands: failure of G protein-coupled
receptor agonists as in vivo imaging agents [abstract]. J. Labelled
Compd. Radiopharm. 1997, 40, 563-564.
(34) Thorell, J. O.; Hedberg, M. H.; Johansson, A. M.; Hacksell, U.; Stone-
Elander, S.; Eriksson, L.; Ingvar, M. (R)-[N-11C-methyl]-11-hydroxy-
10-methylaporphine as a ligand for 5-HT1A receptors: synthesis and
evaluation of its biodistribution in monkey with PET [abstract]. J.
Labelled Compd. Radiopharm. 1995, 44, S179.
(35) Barf, T. A.; Visser, G. M.; van Waarde, A.; Korte, S. M.; Postema,
F.; Leyssen, D.; Van Delft, A. M.; Wikstrom, H.; Bohus, B.; Korf,
J.; Vaalburg, W. Synthesis and biodistribution of [C-11]Org-13502,
a high-affinity serotonin (5-HT1A) receptor ligand [abstract]. J. Nucl.
Med. 1995, 36, 163P.
in membranes from Sf9 cells. Biochemistry 1997, 36, 12930-12938.
15) Watson, J.; Collin, L.; Ho, M.; Riley, G.; Scott, C.; Selkirk, J. V.;
Price, G. W. 5-HT(1A) receptor agonist-antagonist binding affinity
difference as a measure of intrinsic activity in recombinant and native
tissue systems. Br. J. Pharmacol. 2000, 130, 1108-1114.
16) Gozlan, H.; Thibault, S.; Laporte, A. M.; Lima, L.; Hamon, M. The
selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels
both G-protein-coupled and free 5-HT1A receptors in rat brain
membranes. Eur. J. Pharmacol. 1995, 288, 173-186.
(
(
(
17) Mongeau, R.; Welner, S. A.; Quirion, R.; Suranyi-Cadotte, B. E.
Further evidence for differential affinity states of the serotonin1A
receptor in rat hippocampus. Brain Res. 1992, 590, 229-238.
18) Burnet, P. W.; Eastwood, S. L.; Harrison, P. J. [3H]WAY-100635
for 5-HT1A receptor autoradiography in human brain: a comparison
with [3H]8-OH-DPAT and demonstration of increased binding in
the frontal cortex in schizophrenia. Neurochem. Int. 1997, 30, 565-
(
(36) Fujio, M.; Nagata, S.; Kawamura, K.; Sugiyama, N.; Tanaka, H.;
Uno, K.; Ishiwata, K. Synthesis and evaluation of 11C-labeled (S)-
N-{[1-(2-phenylethyl) pyrrolidin-2-yl]methyl}-3-methylthiobenz-
amide as a PET 5-HT1A receptor ligand. Nucl. Med. Biol. 2002, 29,
657-663.
574.
(
19) Kegeles, L. S.; Mann, J. J. In vivo imaging of neurotransmitter
systems using radiolabeled receptor ligands. Neuropsychopharma-
cology 1997, 17, 293-307.
(37) Hwang, D. R.; Ngo, K.; Savenkova, L.; Huang, Y.; Guo, N. N.; Zhu,
Z.; Laruelle, M. 1-[2[(4-[F-18]fluorobenzamido-1-ethyl]4-(1,2,3,4-